DE69635305D1 - Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma - Google Patents

Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Info

Publication number
DE69635305D1
DE69635305D1 DE69635305T DE69635305T DE69635305D1 DE 69635305 D1 DE69635305 D1 DE 69635305D1 DE 69635305 T DE69635305 T DE 69635305T DE 69635305 T DE69635305 T DE 69635305T DE 69635305 D1 DE69635305 D1 DE 69635305D1
Authority
DE
Germany
Prior art keywords
interleukin
antibody
medicament
preparation
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635305T
Other languages
English (en)
Other versions
DE69635305T2 (de
Inventor
Clifford Levitt
W Lee Maloy
U Kari
Nicolas Nicolaides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of DE69635305D1 publication Critical patent/DE69635305D1/de
Publication of DE69635305T2 publication Critical patent/DE69635305T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69635305T 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma Expired - Lifetime DE69635305T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US276595P 1995-08-24 1995-08-24
US2765P 1995-08-24
US2380096P 1996-08-06 1996-08-06
US23800P 1996-08-06
PCT/US1996/012757 WO1997008321A1 (en) 1995-08-24 1996-08-23 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Publications (2)

Publication Number Publication Date
DE69635305D1 true DE69635305D1 (de) 2006-03-02
DE69635305T2 DE69635305T2 (de) 2006-07-06

Family

ID=26670837

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69635305T Expired - Lifetime DE69635305T2 (de) 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69638281T Expired - Lifetime DE69638281D1 (de) 1995-08-24 1996-08-23 Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69638281T Expired - Lifetime DE69638281D1 (de) 1995-08-24 1996-08-23 Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen

Country Status (10)

Country Link
EP (3) EP0846173B1 (de)
JP (3) JP3948495B2 (de)
AT (2) ATE484294T1 (de)
AU (1) AU6895696A (de)
CA (2) CA2666298A1 (de)
DE (2) DE69635305T2 (de)
DK (2) DK1632248T3 (de)
ES (2) ES2249786T3 (de)
PT (1) PT1632248E (de)
WO (1) WO1997008321A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
AU746595B2 (en) * 1996-12-02 2002-05-02 Genaera Corporation IL-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
CA2689842A1 (en) * 1996-12-02 1998-06-11 Genaera Corporation Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
EP1015492A2 (de) * 1997-09-19 2000-07-05 Magainin Pharmaceuticals Inc. Astma-assoziierter faktor als ziel für die behandlung von atopischen allergien, wie astma und verwandten erkrankungen
AU760274B2 (en) * 1997-09-19 2003-05-08 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU781995B2 (en) * 1999-05-01 2005-06-23 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
DE60236643D1 (de) * 2001-02-22 2010-07-22 Univ New York State Res Found Opiatrezeptoren
ATE540695T1 (de) * 2001-06-08 2012-01-15 Genaera Corp Verfahren zur modulation von il-13
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) * 2008-05-22 2014-07-30 日本たばこ産業株式会社 苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
AU2237395A (en) 1994-03-30 1995-10-23 University Of Maryland At Baltimore Human interleukin variants generated by alternative splicing

Also Published As

Publication number Publication date
EP1632248B1 (de) 2010-10-13
ES2249786T3 (es) 2006-04-01
JP2007169287A (ja) 2007-07-05
JP2011152135A (ja) 2011-08-11
ES2354360T3 (es) 2011-03-14
DE69635305T2 (de) 2006-07-06
DE69638281D1 (de) 2010-11-25
ATE484294T1 (de) 2010-10-15
EP1632248A1 (de) 2006-03-08
DK0846173T3 (da) 2006-01-16
EP0846173B1 (de) 2005-10-19
ATE307203T1 (de) 2005-11-15
PT1632248E (pt) 2010-12-28
JP3948495B2 (ja) 2007-07-25
JPH11514851A (ja) 1999-12-21
CA2666298A1 (en) 1997-03-06
EP1632248B8 (de) 2010-12-29
EP2241329A3 (de) 2011-03-09
DK1632248T3 (da) 2011-01-24
CA2230240C (en) 2009-08-18
EP2241329A2 (de) 2010-10-20
EP0846173A1 (de) 1998-06-10
CA2230240A1 (en) 1997-03-06
JP4813380B2 (ja) 2011-11-09
AU6895696A (en) 1997-03-19
WO1997008321A1 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69600307D1 (de) Beatmungsgerät zur Behandlung von Ateminsuffizienzen
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69022249D1 (de) Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
ATE110265T1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer&#39;s krankheit
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69113773D1 (de) Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma.
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69510798T2 (de) Verfahren zur herstellung von kalziumsalzen von [s,s]-äthylendiamin- n,n&#39;-dibernsteinsäure
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805

8327 Change in the person/name/address of the patent owner

Owner name: LIGAND PHARMACEUTICALS INC. (N. D. GES. D. STA, US